Gabri Mariano R, Cacciavillano Walter, Chantada Guillermo L, Alonso Daniel F
a Laboratory of Molecular Oncology , National University of Quilmes , Buenos Aires , Argentina.
b Hematology-Oncology Service , Pediatric Hospital Professor Dr. Juan P. Garrahan , Buenos Aires , Argentina.
Expert Opin Biol Ther. 2016;16(4):573-8. doi: 10.1517/14712598.2016.1157579.
Racotumomab (originally known as 1E10 mAb) is an anti-idiotype murine IgG1 directed to membrane glycoconjugates expressed in aggressive solid tumors. It was developed as a mirror image of the idiotype of another antibody against N-glycolyl-containing molecules, such as the NeuGcGM3 ganglioside. After a successful phase II/III study, racotumomab formulated in alum was conditionally approved in Latin American countries as maintenance therapy for advanced non-small cell lung cancer.
This review analyzes the biology of the target antigen, summarizes preclinical studies and discusses clinical trials in adults and the pediatric experience with racotumomab.
Proper patient selection and combination with chemotherapy, radiotherapy or checkpoint inhibitors appear to be critical issues to maximize the effects of racotumomab vaccination in lung cancer. In a recent phase I clinical trial in children with relapsed or resistant neuroectodermal malignancies, racotumomab was well tolerated and immunogenic, and its evaluation as immunotherapy for high-risk neuroblastoma is warranted.
拉科妥单抗（最初称为1E10单克隆抗体）是一种抗独特型鼠源IgG1，靶向侵袭性实体瘤中表达的膜糖缀合物。它是作为另一种针对含N - 羟乙酰神经氨酸分子（如NeuGcGM3神经节苷脂）的抗体独特型的镜像而开发的。在一项成功的II/III期研究后，用明矾配制的拉科妥单抗在拉丁美洲国家被有条件批准作为晚期非小细胞肺癌的维持治疗药物。
本综述分析了靶抗原的生物学特性，总结了临床前研究，并讨论了成人临床试验以及拉科妥单抗在儿科的应用经验。
正确的患者选择以及与化疗、放疗或检查点抑制剂联合使用似乎是最大化拉科妥单抗疫苗接种在肺癌中效果的关键问题。在最近一项针对复发或耐药神经外胚层恶性肿瘤儿童的I期临床试验中，拉科妥单抗耐受性良好且具有免疫原性，因此有必要对其作为高危神经母细胞瘤免疫疗法进行评估。
